Aurobindo arm CuraTeQ Biologics’ facility secures nod from Brazil’s health regulator
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received approval from Brazil's health regulator, Anvisa, for its biosimilars manufacturing facility in Hyderabad. This certification allows the company to expand its reach into the Latin American market.
Why it matters
Regulatory approvals in international markets are critical for pharmaceutical companies to scale their global operations and export capabilities.
Aurobindo Pharma subsidiary CuraTeQ Biologics’ biosimilars manufacturing facility in Hyderabad has received Brazilian health regulator Anvisa’s approval, enabling it to tap the broader Latin American market..
The facility underwent a good manufacturing practice (GMP) inspection by Anvisa from May 11-15, 2026 and the approval was granted following successful completion of the inspection for biological active pharmaceutical Ingredient (API) and sterile products., Aurobindo Pharma said in a filing on Tuesday.
The scope of the GMP inspection covered four biosimilar products and assessed the mammalian and microbial drug substance manufacturing facility, prefillable syringe and vial filling facility, packaging and labelling facility, QC testing and release laboratories.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in